News

Novel optogenetics gene therapies for patients with blinding diseases

News

Endpoints: On a personal mission for his daughter, Paul Bresge launches another eye disease biotech with $100M for Ray Therapeutics

Press Releases

Ray Therapeutics and Forge Biologics Expand Their Viral Vector cGMP Partnership to Encompass Plasmid DNA Manufacturing

Building on AAV manufacturing partnership with new plasmid production, Forge’s end-to-end manufacturing services will help to advance Ray Therapeutics’ gene therapy for patients living…

Ray Therapeutics Appoints Dr. Peter Francis as Chief Scientific & Medical Officer and Jenny Holt as SVP, Program Portfolio Management

Dr. Francis is a world-renowned clinician scientist and a leader in gene therapy drug development….

Ray Therapeutics Receives $4M in Funding From the California Institute for Regenerative Medicine (CIRM)

The funding will advance development of Ray Therapeutics’ optogenetics technology platform – Company will advance Ray-001 for the treatment of retinitis pigmentosa…

Ray Therapeutics and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership

The manufacturing partnership that will advance Ray Therapeutics’ lead optogenetics gene therapy program, Ray-001, into clinical trials for patients with retinitis pigmentosa….
©Ray Therapeutics. All rights reserved | Site by BKW